Beta Drugs Limited

NSE: BETA
Beta Drugs Limited - pharma in Baddi, Himachal Pradesh, India. FY 2026 financials & compliance.
CIN L24230HP2005PLC028969 Incorporated 21 September 2005 ROC Himachal Pradesh HQ Baddi, Himachal Pradesh, India
Active Listed - NSE: BETA Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹2,057 Cr
BETA · NSE
Share Price
₹1,798.40
-2.77% today
Revenue
₹385 Cr
FY 2025-26 · +6.2% YoY
EBITDA
₹75.68 Cr
Margin 19.7%
Net Profit
₹41.49 Cr
FY 2025-26 · -9.4% YoY
P/E (TTM)
42.3x
P/B 5.0x
Authorised capital
₹11.4 Cr
Registered with MCA
Paid-up capital
₹11.12 Cr
Issued & subscribed

About Beta Drugs Limited

Data last updated:

Beta Drugs Limited is a public limited company based in Baddi, Himachal Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 September 2005 and has been in existence for over 21 years.

The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24230HP2005PLC028969. Its GSTIN is 02AADCB2289C1Z7 (Himachal Pradesh). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on NSE: BETA.

The company has an authorised share capital of ₹11.4 Cr and a paid-up capital of ₹11.12 Cr. It was formerly known as Beta Drugs Private Limited. It is led by directors including Varun Batra (Managing Director) and Rahul Batra (Managing Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village Nandpur, Baddi, Himachal Pradesh, India – 174101.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹384.83 Cr, a growth of 6.2% compared to the previous year. For the same year it recorded a net profit of ₹41.49 Cr (net margin 10.8%) and EBITDA of ₹75.68 Cr (EBITDA margin 19.7%). The net worth stands at ₹244.77 Cr (up 24.2% YoY). Total assets are valued at ₹402.14 Cr (up 16.7% YoY).

The company has about 382 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand: Beta Drugs. As per MCA filings, the company has open charges of ₹57.52 Cr and satisfied charges of ₹24.23 Cr on record. Court records list 58 cases involving the company, including 46 filed by the company and 12 filed against it; 32 cases are pending. The company has 11 deals on record (3 secondary share transfers, 3 market trades, 2 rights issues), with disclosed funding of ₹125.76 Cr; the latest was in November 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Marc Laboratories Limited with revenue of ₹383.21 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2023, listing 886 overdue payments to 66 micro and small suppliers.

Beta Drugs Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HR-13-0000312). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website betadrugslimited.com.

Company details

CIN L24230HP2005PLC028969
Registration Number 028969
Incorporation Date 21 September 2005
ROC Himachal Pradesh
Listing Status Listed - Listed on NSE (BETA)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HR-13-0000312

CIN history

Beta Drugs has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230HP2005PLC028969, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230HP2005PLC028969Current
U24230HP2005PTC028969Previous
U24230HP2005PLC028969Previous
Key People
Varun Batra Managing Director Rahul Batra Managing Director Balwant Singh Whole-Time Director

Recognitions & Rankings of Beta Drugs

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-HR-13-0000312

Contact details

Beta Drugs Limited's registered office is in Baddi, Himachal Pradesh. Its website is betadrugslimited.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    betadrugslimited.com
  • Registered Address
    Village Nandpur, Baddi, Himachal Pradesh, India – 174101
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Beta Drugs Limited, buy the company report.

Comprehensive company report
Beta Drugs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Beta Drugs operates one associated brand: Beta Drugs. Each brand links to its own profile.

BrandDescriptionWebsite
Beta Drugs
Developer of therapeutics for oncology and dermatologybetadrugslimited.com

Business activity

The main business activity of Beta Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Beta Drugs Limited, buy the company report.

Financials of Beta Drugs Limited

FY 2025-26 filings available

Beta Drugs Limited reported revenue of ₹384.83 Cr (up 6.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹385 Cr
+6.2% YoY
EBITDA
₹75.68 Cr
+8.1% YoY
Profit After Tax
₹41.49 Cr
-9.4% YoY
Net Worth
₹245 Cr
+24.2% YoY
Total Assets
₹402 Cr
+16.7% YoY
Total Debt
₹148 Cr
+7.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue38536229622718411690.81
Revenue growth+6.2%+22.5%+30.2%+23.5%+58.3%+27.9%-
EBITDA75.6870.0459.9853.1242.7124.7517.91
EBITDA margin+19.7%+19.3%+20.3%+23.4%+23.2%+21.3%+19.7%
Profit before tax54.4056.9848.7441.0534.3215.9611.97
Net profit41.4945.8036.4230.7124.8411.739.43
Net profit margin+10.8%+12.6%+12.3%+13.5%+13.5%+10.1%+10.4%
EPS (₹)40.9242.0237.9031.9525.8212.209.79
Balance sheet
Total assets40234517814911890.5482.78
Net worth24519715712392.3468.6157.11
Total debt14813814.7120.3320.6017.4622.57
Cash & bank12514728.6319.1617.3210.425.39
Net working capital24222910278.0256.7641.0731.65
Cash flow
Cash from operations37.2936.1430.9323.3829.6318.608.41
Cash from investing(51.39)(35.72)(13.97)(19.07)(21.75)(5.85)(15.05)
Cash from financing(8.07)118(7.49)(2.47)(0.97)(7.71)8.73
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue13712693.9687.2710310093.7688.29
Revenue growth (YoY)+33.0%+25.3%+0.2%-1.2%----
Other income1.751.582.892.312.992.993.960.97
EBITDA30.2827.3717.6716.9921.3119.7115.1216.11
EBITDA margin+22.0%+21.8%+18.8%+19.5%+20.6%+19.7%+16.1%+18.2%
Depreciation4.614.354.804.394.243.733.573.24
Interest1.642.563.944.433.613.323.291.88
Profit before tax25.7822.0411.8210.4816.4515.6512.2211.96
Tax6.495.562.781.954.233.953.203.01
Net profit19.2916.489.048.5312.2211.709.028.95
EPS (₹)16.5914.788.938.4012.1011.599.409.31
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue22522019815812579.4665.32
Revenue growth+2.4%+11.4%+25.2%+26.5%+57.1%+21.7%-
EBITDA28.5426.8433.5331.1925.1915.3111.75
EBITDA margin+12.7%+12.2%+17.0%+19.8%+20.2%+19.3%+18.0%
Profit before tax18.2020.8329.4925.2020.179.888.95
Net profit14.3218.7421.9418.8114.266.987.10
Net profit margin+6.4%+8.5%+11.1%+11.9%+11.4%+8.8%+10.9%
EPS (₹)14.1415.2922.8219.5714.827.267.39
Balance sheet
Total assets28626312510586.7470.4366.20
Net worth15012911696.2577.4663.4156.44
Total debt1301285.685.956.845.198.91
Cash & bank11814227.2017.7915.588.274.16
Net working capital16917768.0755.7438.5927.7621.19
Cash flow
Cash from operations19.2018.0421.1910.2318.7611.606.09
Cash from investing(31.31)(21.46)(11.02)(5.82)(12.72)(3.15)(14.33)
Cash from financing(11.44)118(0.76)(2.19)1.27(4.34)9.48
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.0155.8354.3550.2854.4866.3253.7448.27
Revenue growth (YoY)+6.5%-15.8%+1.1%+4.2%----
Other income1.861.872.922.512.742.973.930.88
Total expenses51.6245.6744.5943.7349.7558.8250.7144.90
EBITDA6.3910.169.766.554.737.503.033.37
EBITDA margin+11.0%+18.2%+18.0%+13.0%+8.7%+11.3%+5.6%+7.0%
Depreciation2.632.492.742.512.382.042.141.92
Interest0.651.602.873.172.972.792.811.33
Profit before tax4.977.947.073.382.125.642.011.00
Tax1.262.001.730.120.611.420.620.25

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue13712693.9687.2710310093.7688.29
Revenue growth (YoY)+33.0%+25.3%+0.2%-1.2%----
Other income1.751.582.892.312.992.993.960.97
EBITDA30.2827.3717.6716.9921.3119.7115.1216.11
EBITDA margin+22.0%+21.8%+18.8%+19.5%+20.6%+19.7%+16.1%+18.2%
Depreciation4.614.354.804.394.243.733.573.24
Interest1.642.563.944.433.613.323.291.88
Profit before tax25.7822.0411.8210.4816.4515.6512.2211.96
Tax6.495.562.781.954.233.953.203.01
Net profit19.2916.489.048.5312.2211.709.028.95
EPS (₹)16.5914.788.938.4012.1011.599.409.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue38536229622718411690.81
Revenue growth+6.2%+22.5%+30.2%+23.5%+58.3%+27.9%-
Other income11.186.441.360.750.760.500.41
Total expenses30929223617414191.3772.90
Employee cost0.0026.8620.1417.0812.108.326.95
EBITDA75.6870.0459.9853.1242.7124.7517.91
EBITDA margin+19.7%+19.3%+20.3%+23.4%+23.2%+21.3%+19.7%
Depreciation17.1512.519.7810.417.256.873.76
Interest15.316.992.822.411.902.422.59
Profit before tax54.4056.9848.7441.0534.3215.9611.97
Tax12.9114.5512.3210.349.484.232.56
Net profit41.4945.8036.4230.7124.8411.739.43
Net profit margin+10.8%+12.6%+12.3%+13.5%+13.5%+10.1%+10.4%
EPS (₹)40.9242.0237.9031.9525.8212.209.79
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.1410.099.619.619.619.619.61
Reserves & surplus23518714811382.7359.0047.50
Shareholders' funds (net worth)24519715712392.3468.6157.11
Minority interest0.000.000.000.000.000.000.00
Secured loans34.9518.9114.7120.3320.6017.4622.54
Unsecured loans1131190.000.000.000.000.03
Total debt14813814.7120.3320.6017.4622.57
Total liabilities40234517814911890.5482.78
Assets
Gross block20014610999.3782.1761.1458.29
Net block12588.9364.5962.7654.9539.9743.83
Capital work in progress0.000.000.000.000.002.810.08
Investments0.000.000.000.780.780.780.35
Inventories74.4659.7749.8130.6222.4816.0412.35
Sundry debtors11910379.2462.7245.1833.8831.93
Cash & bank balances12514728.6319.1617.3210.425.39
Loans & advances16.7211.0120.1815.1811.977.706.37
Total current assets33532017812896.9568.0456.04
Total current liabilities93.6591.6776.0049.6640.1926.9724.39
Net working capital24222910278.0256.7641.0731.65
Total assets40234517814911890.5482.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14728.6319.1617.3210.425.393.30
Net cash from operating activities37.2936.1430.9323.3829.6318.608.41
Net cash from investing activities(51.39)(35.72)(13.97)(19.07)(21.75)(5.85)(15.05)
Net cash from financing activities(8.07)118(7.49)(2.47)(0.97)(7.71)8.73
Net change in cash(22.18)1189.471.846.905.042.09
Closing cash12514728.6319.1617.3210.425.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.2%+22.5%+30.2%+23.5%+58.3%+27.9%-
EBITDA growth+8.1%+16.8%+12.9%+24.4%+72.6%+38.2%-
PBT growth-4.5%+16.9%+18.7%+19.6%+115.0%+33.3%+51.3%
Net income growth-9.4%+25.8%+18.6%+23.6%+111.8%+24.4%-
Revenue CAGR (3Y)+19.2%+25.4%+36.6%+35.7%+40.8%+31.9%-
EBITDA CAGR (3Y)+12.5%+17.9%+34.3%+43.7%+53.5%+37.8%-
Profitability & leverage
Net income margin+10.8%+11.7%+12.3%+13.5%+13.5%+10.1%+10.4%
Return on capital employed-+24.5%+31.6%+32.6%+34.8%+21.2%+20.0%
Return on net worth-+24.0%+26.0%+28.6%+30.9%+18.6%+19.2%
Debt / equity-0.430.130.190.240.320.43
Long-term debt / equity-0.380.050.090.140.170.18
Interest cover26.1612.155.625.645.3613.5318.30
Efficiency & per share
Fixed asset turnover-2.832.832.502.571.942.17
Inventory turnover-6.617.358.559.558.188.30
Debtors turnover-3.994.174.214.653.533.19
EPS (₹)40.9242.0237.9031.9525.8212.209.79
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00195.25163.43127.8296.0571.3759.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.0155.8354.3550.2854.4866.3253.7448.27
Revenue growth (YoY)+6.5%-15.8%+1.1%+4.2%----
Other income1.861.872.922.512.742.973.930.88
Total expenses51.6245.6744.5943.7349.7558.8250.7144.90
EBITDA6.3910.169.766.554.737.503.033.37
EBITDA margin+11.0%+18.2%+18.0%+13.0%+8.7%+11.3%+5.6%+7.0%
Depreciation2.632.492.742.512.382.042.141.92
Interest0.651.602.873.172.972.792.811.33
Profit before tax4.977.947.073.382.125.642.011.00
Tax1.262.001.730.120.611.420.620.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue22522019815812579.4665.32
Revenue growth+2.4%+11.4%+25.2%+26.5%+57.1%+21.7%-
Other income11.146.191.731.040.860.610.42
Total expenses19719316412799.6664.1553.57
Employee cost0.0015.0011.0810.316.704.533.70
EBITDA28.5426.8433.5331.1925.1915.3111.75
EBITDA margin+12.7%+12.2%+17.0%+19.8%+20.2%+19.3%+18.0%
Depreciation9.677.444.726.195.475.272.58
Interest11.814.761.050.840.410.770.64
Profit before tax18.2020.8329.4925.2020.179.888.95
Tax3.885.417.556.395.912.901.85
Net profit14.3218.7421.9418.8114.266.987.10
Net profit margin+6.4%+8.5%+11.1%+11.9%+11.4%+8.8%+10.9%
EPS (₹)14.1415.2922.8219.5714.827.267.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.1410.099.619.619.619.619.61
Reserves & surplus13911910686.6467.8553.8046.83
Shareholders' funds (net worth)15012911696.2577.4663.4156.44
Secured loans20.3810.555.685.956.845.198.88
Unsecured loans1101170.000.000.000.000.03
Total debt1301285.685.956.845.198.91
Total liabilities28626312510586.7470.4366.20
Assets
Gross block12189.5265.1259.8453.8643.1541.54
Net block75.6353.4836.4834.7734.0528.0131.67
Capital work in progress0.000.000.000.000.001.900.08
Investments5.775.775.776.556.546.546.12
Inventories31.4227.4421.9413.668.477.706.10
Sundry debtors53.8148.5850.4943.5931.3520.8120.91
Cash & bank balances11814227.2017.7915.588.274.16
Loans & advances14.5713.2114.059.957.356.786.00
Total current assets21823111484.9962.7543.5637.17
Total current liabilities49.0453.7845.6129.2524.1615.8015.98
Net working capital16917768.0755.7438.5927.7621.19
Total assets28626312510586.7470.4366.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14227.2017.7915.588.274.162.92
Net cash from operating activities19.2018.0421.1910.2318.7611.606.09
Net cash from investing activities(31.31)(21.46)(11.02)(5.82)(12.72)(3.15)(14.33)
Net cash from financing activities(11.44)118(0.76)(2.19)1.27(4.34)9.48
Net change in cash(23.55)1159.402.217.314.101.24
Closing cash11814227.2017.7915.588.274.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.4%+11.4%+25.2%+26.5%+57.1%+21.7%-
EBITDA growth+6.3%-20.0%+7.5%+23.8%+64.5%+30.3%-
PBT growth-12.6%-29.4%+17.0%+24.9%+104.2%+10.4%+19.8%
Net income growth-23.6%-14.6%+16.6%+31.9%+104.3%-1.7%-
Revenue CAGR (3Y)+12.6%+20.8%+35.5%+34.2%+29.1%+16.3%+16.2%
EBITDA CAGR (3Y)-2.9%+2.1%+29.9%+38.5%+34.7%+17.4%+17.3%
Profitability & leverage
Net income margin+6.4%+7.0%+11.1%+11.9%+11.4%+8.8%+10.9%
Return on capital employed-+15.6%+26.6%+27.2%+26.2%+15.6%+16.6%
Return on net worth-+15.3%+20.7%+21.7%+20.2%+11.7%+14.6%
Debt / equity-0.540.050.070.090.120.17
Long-term debt / equity-0.520.030.050.060.060.09
Interest cover62.5924.543.643.362.087.676.98
Efficiency & per share
Fixed asset turnover-2.853.162.782.571.882.14
Inventory turnover-8.9211.1014.2715.4411.5210.44
Debtors turnover-4.454.204.214.793.813.42
EPS (₹)14.1415.2922.8219.5714.827.267.39
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00127.83120.67100.1280.5765.9658.71

To see the full year-wise statements and ratios of Beta Drugs Limited, buy the company report.

Board of directors of Beta Drugs Limited

Beta Drugs has 10 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Balwant SinghWhole-Time Director01 Aug 201412 Years 2 MonthsCurrent
Rohit PartiDirector26 Jul 20179 Years 3 MonthsCurrent
Manmohan KhannaDirector26 Jul 20179 Years 3 MonthsCurrent
Varun Batra
Also directs: Adley Lab Limited, Adley Formulations Private Limited, Beta Research Private Limited and 2 more
Managing Director01 Aug 201412 Years 2 MonthsCurrent
Rahul Batra
Also directs: Adley Lab Limited, Adley Formulations Private Limited, Beta Research Private Limited and 1 more
Managing Director01 Aug 201412 Years 2 MonthsCurrent
Ashutosh ShuklaWhole-Time Director20 Jan 20224 Years 9 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Beta Drugs Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Beta Drugs Limitedthis company₹384.83 Cr (FY 2026)₹41.49 Cr10.8%6.2%382Baddi, Himachal Pradesh, India
Marc Laboratories Limited₹383.21 Cr (FY 2025)3.0%New Delhi, Delhi, India
Caplin Steriles Limited₹377.24 Cr (FY 2025)18.0%Chennai, Tamil Nadu, India
NGL Fine-Chem Limited₹376.89 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Unicure India Ltd₹369.12 Cr (FY 2025)-12.0%New Delhi, Delhi, India
Brawn Laboratories Limited₹368.56 Cr (FY 2025)15.0%Delhi, India
M. J. Biopharm Private Limited₹367.26 Cr (FY 2025)24.0%Pune, Maharashtra, India
Biochem Pharmaceutical Industries Limited Part IX₹366.61 Cr (FY 2016)15.0%Ahmedabad, Gujarat, India
Kopran Research Laboratories Limited₹365.89 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Geltec Private Limited₹362.73 Cr (FY 2025)7.0%Mumbai, Maharashtra, India

To see the full peer comparison of Beta Drugs Limited, buy the company report.

Auditor

Beta Drugs Limited is audited by KALRA RAI & ASSOCIATES for the financial year 2024.

Auditor firmFinancial yearFirm registration number
KALRA RAI & ASSOCIATESFY 2024008859N

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 59.10%, foreign institutional investors hold 1.00%, domestic institutional investors hold 6.20% and retail and other public shareholders hold 33.70%.

Promoters: 59.10%DII (Domestic Institutional): 6.20%FII (Foreign Institutional): 1.00%Retail & Others: 33.70%
Sep 2026
QUARTER
59.10% Promoters
6.20% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
33.70% Retail & Others
Promoter holding - history
Now 59.10% · Sep 2026High 66.70% · Dec 2025Low 59.10% · Sep 2026
58%60.5%63%65.5%68%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 66.70%Mar 2026: 64.90%Jun 2026: 64.60%Sep 2026: 59.10%66.70%59.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters59.10%64.60%64.90%66.70%
Public40.90%35.40%35.10%33.30%

Charges & borrowings

Open charges
₹57.52 Cr
Satisfied charges
₹24.23 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹28.50 Cr
Sidbi₹10.42 Cr
Others₹9.11 Cr
Uco Bank₹7.50 Cr
Axis Bank Limited₹1.98 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
08 Sep 2025101152706Sidbi₹1.42 CrOpen
02 Jul 2025101125694Sidbi₹1.5 CrOpen
15 May 2025101097354Others₹7 CrOpen
29 Mar 2025101087164Axis Bank Limited₹1.98 CrOpen
27 Mar 2025101074956Sidbi₹3 CrOpen

To see the full charge records of Beta Drugs Limited, buy the company report.

Total charge records: 47 View all charges

Deals & funding

Beta Drugs Limited has 11 deals on record (3 secondary share transfers, 3 market trades, 2 rights issues), with disclosed funding of ₹125.76 Cr; the latest was in November 2025.

Total deals
11
Secondary share transfers
3
Market trades
3
Rights issues
2
IPO
1
Disclosed funding
₹125.76 Cr

Deals on record (5 of 11)

WhenDealAmountParties
Nov 2025Market trade₹31.21 CrBuyer: Airavat Capital Trust Ii
Seller: an individual
Sep 2020Market trade₹42.8 LakhBuyer: an individual
Jul 2020Market trade₹1.03 CrBuyer: an individual
Seller: Adesh Ventures LLP
Jul 2020Secondary share transferUndisclosedBuyer: an individual
Seller: Adesh Ventures
May 2019Funding round₹8.74 CrInvestors: Suryavanshi Commotrade Pvt Ltd , 3 individuals

To see the full deal history of Beta Drugs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Beta Drugs Limited was last rated by Crisil on 30 Nov 2020.

Rating agencyRated onRating
Crisil30 Nov 2020

To see the full credit ratings and regulatory alerts of Beta Drugs Limited, buy the company report.

MSME payment delays

Beta Drugs Limited has 12 MSME Form 1 returns on record between 2019 and 2023, listing 886 overdue payments to 66 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 66)

SupplierAmount dueDue sinceReported on
Adley Lab Limited
Arihant Labels
BBN Foils
Aps Imperia Private Limited
an individual supplier

To see the full MSME payment records of Beta Drugs Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Beta Drugs has 3 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

3
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Adley Lab LimitedU24231PB1992PLC051220
Adley Formulations Private LimitedU24303HR2018PTC076347
Beta Reseach Private LimitedU24303HR2022PTC104598

To see the full group structure of Beta Drugs Limited, buy the company report.

Employees & EPFO

Beta Drugs Limited has a workforce of 382 employees on its EPFO records as of Mar 31, 2025, across 1 active EPFO establishment.

Employee count
382
Active EPFO establishments
1
Employee growth
23.62%

GST

Beta Drugs has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
02AADCB2289C1Z7Himachal PradeshActive01 Jul 2017
06AADCB2289C1ZZHaryanaActive23 Jan 2018

To see the full GST registrations and return filing status of Beta Drugs Limited, buy the company report.

Recent activity

Beta Drugs Limited has 31 board changes on record since 2005: 21 appointments and 10 cessations. The latest: Lalit Kumar Watts was appointed as Director on 05 Feb 2025.

Charges
A charge with Hdfc Bank Limited of Rs. 28.50 Cr registered on 08 Oct 2020 with Charge ID 100379428 was modified on 16 Apr 2026.
Filing
Beta Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Himachal Pradesh.
Charges
A charge registered on 25 Feb 2022 via Charge ID 100560537 with Axis Bank Limited was fully satisfied on 11 Feb 2026.
Charges
A charge registered on 19 Oct 2022 via Charge ID 100621156 with Hdfc Bank Limited was fully satisfied on 07 Jan 2026.
Charges
A charge registered on 29 Aug 2022 via Charge ID 100603178 with Hdfc Bank Limited was fully satisfied on 05 Dec 2025.
Charges
A charge registered on 29 Jul 2024 via Charge ID 100955576 with Hdfc Bank Limited was fully satisfied on 03 Dec 2025.
AGM
Beta Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Sidbi amounted to Rs. 1.42 Cr with Charge ID 101152706 was registered on 08 Sep 2025.
Charges
A charge with Sidbi amounted to Rs. 1.50 Cr with Charge ID 101125694 was registered on 02 Jul 2025.
Charges
A charge with Others amounted to Rs. 7.00 Cr with Charge ID 101097354 was registered on 15 May 2025.
Charges
A charge registered on 23 Sep 2020 via Charge ID 100375444 with Others was fully satisfied on 24 Apr 2025.
Charges
A charge registered on 27 Dec 2019 via Charge ID 100323044 with Others was fully satisfied on 24 Apr 2025.

105 earlier events are in the company report.

News

BETA: Q2 CONS NET PROFIT 193M RUPEES VS 120M (YOY)
22 Oct 2026 · Exchange Update
BETA: Q2 REVENUE 1.37B RUPEES VS 1B (YOY)
22 Oct 2026 · Exchange Update
BETA: Q2 EBITDA 303M RUPEES VS 213M (YOY); Q2 EBITDA MARGIN 22.02% VS 20.6% (YOY)
22 Oct 2026 · Exchange Update
Beta Drugs: Gets Azerbaijan Approval For Oncology Products, Aiming For Sales In FY27.
22 Sep 2026 · Exchange Update

Frequently asked questions

Beta Drugs is an active public limited company based in Baddi, Himachal Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 September 2005 (21+ years old) and is registered under CIN L24230HP2005PLC028969. Listed on NSE: BETA.

Beta Drugs reported revenue of ₹384.83 Cr for FY 2025-26 (up 6.2% YoY) based on consolidated financials.

Beta Drugs has 10 current directors:

The latest financial statements of Beta Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Beta Drugs is 02AADCB2289C1Z7, registered in Himachal Pradesh. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 06AADCB2289C1ZZ (Haryana).

The CIN (Corporate Identification Number) of Beta Drugs is L24230HP2005PLC028969. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Beta Drugs is a listed company as per MCA records. Its shares are listed on NSE (symbol: BETA).

Beta Drugs has 58 court cases on record: 46 filed by the company and 12 filed against it. 32 are pending. Most are in the district courts.

Beta Drugs was incorporated on 21 September 2005, making it 21+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.

Beta Drugs has 11 deals on record (3 secondary share transfers, 3 market trades, 2 rights issues), with disclosed funding of ₹125.76 Cr; the latest was in November 2025.

The peers of Beta Drugs by revenue are Marc Laboratories Limited, Caplin Steriles Limited, NGL Fine-Chem Limited, Unicure India Ltd, Brawn Laboratories Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Lalit Kumar Watts was appointed as Director on 05 Feb 2025. Monica Jain was appointed as Director on 05 Feb 2025. Seema Chopra ceased to be Whole-Time Director on 05 Feb 2025. Beta Drugs has 31 board changes on record in total.